CORD-19:5e8abc62533a447422d5ead64d4ae4991cc99052 / 56998-57265 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T445","span":{"begin":0,"end":267},"obj":"Sentence"},{"id":"T62709","span":{"begin":0,"end":267},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Interestingly, XKB shared a number of molecular targets with probucol, which was initially developed as an antihyperlipidemic drug for the treatment of coronary artery diseases but was removed from the USA market in 1995 after it was found to prolong the QT interval."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T21","span":{"begin":243,"end":266},"obj":"Phenotype"}],"attributes":[{"id":"A21","pred":"hp_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/HP_0001657"}],"text":"Interestingly, XKB shared a number of molecular targets with probucol, which was initially developed as an antihyperlipidemic drug for the treatment of coronary artery diseases but was removed from the USA market in 1995 after it was found to prolong the QT interval."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T85","span":{"begin":152,"end":167},"obj":"Body_part"},{"id":"T86","span":{"begin":161,"end":167},"obj":"Body_part"}],"attributes":[{"id":"A85","pred":"uberon_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/UBERON_0001621"},{"id":"A86","pred":"uberon_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/UBERON_0001637"}],"text":"Interestingly, XKB shared a number of molecular targets with probucol, which was initially developed as an antihyperlipidemic drug for the treatment of coronary artery diseases but was removed from the USA market in 1995 after it was found to prolong the QT interval."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T36","span":{"begin":152,"end":176},"obj":"Disease"},{"id":"T19836","span":{"begin":152,"end":176},"obj":"Disease"},{"id":"T6030","span":{"begin":152,"end":176},"obj":"Disease"}],"attributes":[{"id":"A36","pred":"mondo_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/MONDO_0005010"},{"id":"A91040","pred":"mondo_id","subj":"T19836","obj":"http://purl.obolibrary.org/obo/MONDO_0005010"},{"id":"A21427","pred":"mondo_id","subj":"T6030","obj":"http://purl.obolibrary.org/obo/MONDO_0005010"}],"text":"Interestingly, XKB shared a number of molecular targets with probucol, which was initially developed as an antihyperlipidemic drug for the treatment of coronary artery diseases but was removed from the USA market in 1995 after it was found to prolong the QT interval."}